SCHEMBL763394

SCHEMBL763394

NC(=O)c1cnc(Nc2ccc(N3CCN(C(N)=O)CC3)cc2)nc1Nc1ccc2cn[nH]c2c1

nearest known ligand 0.87

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SYK P43405 15/20 0.87
EGFR P00533 1/20 0.63
FGFR1 P11362 1/20 0.63
PDGFRB P09619 4/20 0.59
PDGFRA P16234 4/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL736542 0.93 SYK (1.00) SYKEGFRFGFR1
SCHEMBL764416 0.90 SYK (0.80) SYKEGFRFGFR1PDGFRBPDGFRA
SCHEMBL763498 0.90 SYK (0.80) SYKEGFRFGFR1PDGFRBPDGFRA
SCHEMBL764438 0.88 SYK (0.79) SYKEGFRFGFR1PDGFRBPDGFRA
SCHEMBL28638852 0.83 EGFR (0.77) SYKEGFRFGFR1PDGFRBPDGFRA
SCHEMBL763271 0.82 SYK (0.88) SYK
SCHEMBL10242654 0.82 SYK (0.73) SYKEGFRPDGFRBPDGFRA
SCHEMBL10241915 0.82 SYK (0.73) SYKEGFRPDGFRBPDGFRA
SCHEMBL736081 0.80 SYK (1.00) SYK
SCHEMBL764418 0.80 SYK (0.67) SYKEGFRFGFR1PDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138339-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-03-20 US disclosed
US-20090318407-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318407-A1 Inhibitors of protein kinases SYK, BTK, JAK1 SYK 1/4885EGFR 966/4885FGFR1 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.